Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has C. Neslusan's publication output changed over time?
ScholarIQpublication output · 2000–2020
Output grew0% over the shown period — from 1 works in 2000 to 1 in 2020.
1
1
2
1
1
1
1
2
1
200020012002200320152016201820192020
What are the most-cited papers on C. Neslusan?
ScholarIQmost cited works
Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits
Jodi Crystal-Peters, C. Neslusan, William H. Crown, Amelito Torres
Journal of Allergy and Clinical Immunology. 2002354 CitationsOPEN ACCESS
Explaining Drug Spending Trends: Does Perception Match Reality?
Robert W. Dubois, Anita Chawla, C. Neslusan, Mark W. Smith, Sally Wade
S4210185023. 2000120 Citations
Recent Antihyperglycemic Prescribing Trends for U.S. Privately Insured Patients With Type 2 Diabetes
Fredric J. Cohen, C. Neslusan, Jonathan E. Conklin, Xue Song
Diabetes Care. 2003103 CitationsOPEN ACCESS
Lifetime benefits of early detection and treatment of diabetic kidney disease
Julia Thornton Snider, Jeffrey Sullivan, Emma van Eijndhoven, Michael K. Hansen, Nobel Bellosillo, C. Neslusan, Ellen O’Brien, Ralph Riley, Seth A. Seabury, Bertram L. Kasiske
PLoS ONE. 201944 CitationsOPEN ACCESS
Hospitalization and Total Medical Costs for Privately Insured Persons with Schizophrenia
William H. Crown, C. Neslusan, Patrícia A. Russo, Sue Holzer, Ron Ozminkowski, Thomas W. Croghan
S106668787. 200126 Citations
Related on ScholarIQ
Johnson & Johnson (United States)
Institution
Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits
Paper
Explaining Drug Spending Trends: Does Perception Match Reality?
Paper
Recent Antihyperglycemic Prescribing Trends for U.S. Privately Insured Patients With Type 2 Diabetes
Paper
Lifetime benefits of early detection and treatment of diabetic kidney disease
Paper
Hospitalization and Total Medical Costs for Privately Insured Persons with Schizophrenia
Paper